There were many stocks that recorded significant gains on Monday and one of those was that of Entera Bio (NASDAQ: ENTX).
Yesterday, the stock soared by as high as 152% after the company released the data from the Phase 2 trial of one of its products. Moreover, the stock is up another 52% in the pre-market session on Friday. The product in question is EB 613, which is meant for treating patients who suffer from osteoporosis patients. Considering this development and the strong rally in the Entera stock, investors could look into the company a bit more closely.
One of the most important findings from the study was the fact that EB 613 helped bring about a significant rise in P1NP biomarker. More importantly, it should be noted by investors that the rise in P1NP biomarker was the primary endpoint of the clinical trial. Despite the positivity surrounding the product at this point, it should be noted that the study is still only halfway through. Treatments are expected to last for six more months.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.